Amir H. Hamrahian, MD, is a Staff member in the Department of Endocrinology, Diabetes and Metabolism at Cleveland Clinic's main campus, having accepted that appointment in 2005. Prior to that appointment, he was also a clinical associate there for nearly five years.
His clinical interests include pituitary and adrenal disorders.
Dr. Hamrahian received his medical degree from Hacettepe University in Ankara, Turkey, and upon graduation was a general practitioner in the provinces of Hamadan and Tehran, Iran. He completed an internal medicine residency at the University of North Dakota, Fargo, and an endocrinology fellowship at Case Western Reserve University and University Hospitals, Cleveland.
In 2003, he received the Teacher of the Year award from Cleveland Clinic's Department of Endocrinology, Diabetes and Metabolism. Dr. Hamrahian speaks three languages -- English, Turkish and Farsi -- and is board-certified in internal medicine as well as endocrinology, diabetes and metabolism. He is a member of the Endocrine Society, Pituitary Society and the American Association of Clinical Endocrinologists.
Some of the questions answered in this interview October 1, 2012 include (not in this order):
Listen to this interview at http://www.blogtalkradio.com/cushingshelp/2012/10/01/dr-amir-hamrahian-answers-our-questions or to the podcast by searching for Cushings in the iTunes podcast area or click here: http://itunes.apple.com/podcast/cushingshelp-cushie-chats/id350591438
October 1, 2012 at 6:30 PM eastern, Dr. Amir Hamrahian will answer our questions about Cushing's, pituitary or adrenal issues and Korlym (mifepristone) in BlogTalkRadio at http://www.blogtalkradio.com/cushingshelp/2012/10/01/dr-amir-hamrahian-answers-our-questions
You may listen live at the link above. The episode will be added to the Cushing's Help podcast after the show is over. Listen to the podcasts by searching for Cushings in the iTunes podcast area or click here: http://itunes.apple.com/podcast/cushingshelp-cushie-chats/id350591438
Dr. Hamrahian has had patients on Korlym for about 4 years.
Please submit your questions below or email them to CushingsHelp@gmail.com before Sunday, September 30.
From Dr. Hamrahian's bio at http://my.clevelandclinic.org/staff_directory/staff_display.aspx?doctorid=3676
Appointed: 2000
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Amir H. Hamrahian, MD, is a Staff member in the Department of Endocrinology, Diabetes and Metabolism at Cleveland Clinic's main campus, having accepted that appointment in 2005. Prior to that appointment, he was also a clinical associate there for nearly five years.
His clinical interests include pituitary and adrenal disorders.
Dr. Hamrahian received his medical degree from Hacettepe University in Ankara, Turkey, and upon graduation was a general practitioner in the provinces of Hamadan and Tehran, Iran. He completed an internal medicine residency at the University of North Dakota, Fargo, and an endocrinology fellowship at Case Western Reserve University and University Hospitals, Cleveland.
In 2003, he received the Teacher of the Year award from Cleveland Clinic's Department of Endocrinology, Diabetes and Metabolism. Dr. Hamrahian speaks three languages -- English, Turkish and Farsi -- and is board-certified in internal medicine as well as endocrinology, diabetes and metabolism. He is a member of the Endocrine Society, Pituitary Society and the American Association of Clinical Endocrinologists.
Corcept is providing a nurse to help with insurance and other topics.
If you want a person to talk with her contact info is:
Kate Tully, R.N., B.S.N.
(650) 688-2804
ktully@corcept.com
Cushing’s Patient Advocate
Corcept Therapeutics
149 Commonwealth Drive
Menlo Park, CA 94025
More information about Korlym at http://www.korlym.com
Support Cushing's ...With A Click.
From Corcept, the makers of Korlym:
They say: "Corcept Therapeutics will donate $5 for every person who clicks to support people with Cushing's. Corcept has jump-started the effort to build awareness and support with a $15,000 contribution to provide support through the Cushing's Support and Research Foundation and Cushing's Help. With your support, we can aim even higher!*
Take part...and spread the word.
*Donations up to $30,000. Program ends April 20, 2012"
Pharma-watchers know that rare diseases are all the rage these days. With primary-care blockbusters falling to generic competition, drugmakers are zeroing in on ultra-expensive treatments for conditions that affect only a few hundred patients, rather than millions of them. And companies don't just benefit from the ability to command high prices. They also save on sales reps and ad campaigns.
For pharma sales reps, it may seem like adding insult to injury, after the past several years of mass layoffs. But as Medical Marketing & Media reports, companies won't be staffing up much to launch rare-disease drugs. Take Corcept Therapeutics ($CORT), now preparing to roll out its Cushing's syndrome drug Korlym. "I don't have to hire an army of sales reps," Corcept VP Steven Lo tellsMM&M.
Instead, Corcept will target just 300 endocrinologists to reach the 5,000 or so Cushing's patients Korlym could benefit (of the total 20,000 in the U.S.). Those 300 doctors handle 70% of Cushing's cases in the U.S., Lo says. Corcept will send out medical liaisons, supported by professional advertising and CME. An agency that specializes in orphan and specialty meds will handle advertising to patients and online.
Korlym will no doubt benefit from another advantage that rare-disease drugs usually enjoy: They have no competitors. Cushing's patients who haven't benefited from surgery don't have other drugs to turn to. It will be Korlym or nothing. At what price has yet to be seen; Corcept hasn't yet said how much it will charge for the drug.
Read more: Rare-disease drugs won't help out-of-work pharma reps - FiercePharma
Working on a new video with Beth G. as my partner. With Corlum now thrown in the mix, we want to compare the best treatment options for recurring cushings. We want to hear from you about weather you are glad you had a BLA? if you could do it over again, would you? If you had meds available, did you try them first? What challanges do you have on a regular basis because of BLA? Why would you not want a BLA? What do you hope to get out of having a BLA?
We are not looking for the medical side, just the human side. If you would like to participate, message both Beth and myself on the same message. If you have a webcam, we would like to include video into the video and set up an interview.Remember, its all about Awareness!
I'm working on a questionnaire so that everybody can answer the same set of questions. Trisha or I will email it so you to fill out, so can anybody interested please send us your email address? We're interested in you if:
a) You've had a BLAb) You're considering a BLAc) You're a potential candidate but would never consider a BLAPLEASE REMEMBER: Any information you provide related to a BLA will become public, so if you're not willing to have your thoughts and answers shared with the public (meaning outside of this group in a video that will hopefully go viral on youtube!) then please don't sign up to help with this project!Feel free to ask us questions! Thanks!!
Theodore C. Friedman, M.D., Ph.D. has opened a private practice, specializing in treating patients with adrenal, pituitary, thyroid and fatigue disorders. Dr. Friedman has privileges at Cedars-Sinai Medical Center and Martin Luther King Medical Center. His practice includes detecting and treating hormone imbalances, including hormone replacement therapy. Dr. Friedman is also an expert in diagnosing and treating pituitary disorders, including Cushings disease and syndrome.
Dr. Friedman's career reflects his ongoing quest to better understand and treat endocrine problems. With both medical and research doctoral degrees, he has conducted studies and cared for patients at some of the country's most prestigious institutions, including the University of Michigan, the National Institutes of Health, Cedars-Sinai Medical Center, and UCLA's Charles Drew University of Medicine and Science.
Read Dr. Friedman's First Guest Chat, November 11, 2003.
Read Dr. Friedman's Second Guest Chat, March 2, 2004.
Listen to Dr. Friedman First Live Voice Interview, January 29, 2009.
Listen to Dr. Friedman Second Live Voice Interview, March 12, 2009.
Listen to Dr. Friedman Third Live Voice Interview, February 13, 2011.
Listen live at http://www.blogtalkradio.com/cushingshelp/2012/03/13/questions-about-medical-therapies-for-cushings
Call in to ask your question at
(646) 200-0162
This interview will be archived afterwards at the same link and on iTunes Cushie Podcasts
Korlym was approved February 17th, 2012 for persistant Cushing's. More information here.
Corcept will hold a conference call on Tuesday, February 21, 2012 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) to discuss this announcement. To participate in the live call please dial 1-800-264-7882 from the United States or +1-847-413-3708 internationally. The pass code is 31838602. Please dial in approximately 10 minutes before the start of the call.
A replay of the conference call will be available through March 6, 2012 at 1-888-843-7419 from the United States and +1-630-652-3042 internationally. The pass code is 31838602.
